Aspartate Aminotransferase

NEW ORLEANS — New real-world data demonstrate safety and effectiveness of macitentan for the treatment of pulmonary arterial hypertension associated with systemic sclerosis, with outcomes consistent with those in idiopathic and heritable PAH, researchers reported at the CHEST Annual Meeting.

Approximately 30% of Americans have fatty liver, but only a small proportion have progressed to nonalcoholic steatohepatitis. One of the complications that we face in finding these patients is that our current treatment guidelines for nonalcoholic fatty liver disease do not recommend routine screening. Additionally, it is not feasible to send every patient with potential risk factors for an invasive procedure like liver biopsy. What we have at our disposal, however, are some very simple noninvasive biomarkers and tools to help stratify which patients should be followed for fatty liver and its progression.

PARIS — Inclisiran, an investigational cholesterol-lowering therapy in the small-interfering RNA class, achieved durable and potential LDL reduction with twice-yearly injections, according to new data from the ORION-11 study.

Altered liver function markers appeared associated with Alzheimer’s disease diagnosis and impaired memory and executive function, as well as amyloid-, tau and neurodegenerative biomarkers of Alzheimer’s pathophysiology, according to study results published in JAMA Network Open.